Keros Therapeutics
Keros Therapeutics works on 3 rare diseases tracked on Trial Friend, including Duchenne Muscular Dystrophy, Myelofibrosis, Pulmonary Arterial Hypertension, with 1 recruiting clinical trial.
Keros Therapeutics is a clinical-stage biopharmaceutical company developing therapies for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-beta) family of proteins. The company's lead product candidate, rinvatercept, is in development for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its most advanced product candidate, elritercept (KER-050), is in development for cytopenias including anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis, and is partnered with Takeda. Keros discontinued its PAH program (cibotercept/KER-012) in May 2025 following the failed TROPOS Phase 2 trial.
Keros Therapeutics Drug Pipeline
Keros Therapeutics has 1 active clinical trial across 1 development stage, with 1 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Keros Therapeutics Clinical Trials (1)
Active and recruiting clinical trials sponsored by Keros Therapeutics, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Keros Therapeutics. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Duchenne Muscular Dystrophy. Turn any of these off from the link in every email.
FDA-Approved Drugs
Keros Therapeutics Trial Locations
Keros Therapeutics clinical trials are running at 2 sites in 1 country. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (3)
Diseases targeted by Keros Therapeutics's clinical trial and drug development programs
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginning in early childhood. The defective dystrophin protein normally protects muscl...
Myelofibrosis is a myeloproliferative neoplasm in which bone marrow develops scarring (fibrosis), leading to anemia, enlarged spleen, and abnormal blood cell counts. Most cases involve JAK2, CALR, or ...
Pulmonary arterial hypertension is a rare disease characterized by abnormally high blood pressure in the pulmonary arteries, causing progressive heart and lung damage. The disease involves vasoconstri...
Patient Resources
Organizations and resources related to Keros Therapeutics's rare disease focus areas
Frequently Asked Questions About Keros Therapeutics
Common questions about Keros Therapeutics's rare disease programs, clinical trials, and treatments.